



Dr.K.V. Subba Reddy Institute of Pharmacy

(Approved by AICTE, P. C. I. New Delhi & Permanently Affiliated to JNTUA Anantapuramu,

MOU with Government General Hospital & KMC, Kurnool)

Recognized Under Section 2(f) and 12(B) of UGC Act 1956 Opp: Dupadu R.S., N.H.-44, KURNOOL-518218, A.P. INDIA.


Tree Plantation

Dr. K.V. Subba Reddy Institute of Pharmacy & NSS Unit has combinedly conducted TREE PLANTATION PROGRAMME in Peddatekuru village on 22-10-2021 within the campus. The students are instructed how to do plantation by their respective faculties. Our respected Chairman, Principal, all Faculties and Students are shared their valuable words. They educated everyone about the importance of Plantation and keeping our surroundings green. In this programme Dr. K.V. Subba Reddy Chairman of Dr. KVSR group of Institutions, Dr. G. Nagarajan Principal of Dr. KVSP, NSS coordinator Naganjaneyulu, students and staff were present.




Tree plantation by Dr. KVSP Staff and Students




Principal
Dr. K.V.S.R. Institute of Pharmacy
Opp: Dupadu R.S. N.H.-44,
KURNOOL-518218 (A.P.)

Cell : 9704 333 789
9177287508
7660003344



Dr. K.V. Subba Reddy Institute of Pharmacy

(Approved by AICTE, P.C.I. New Delhi & Permanently Affiliated to JNTUA Anantapuramu,
MOU with Government General Hospital & KMC, Kurnool)
Recognized Under Section 2(f) and 12(B) of UGC Act 1956
Opp : Dupadu R.S., N.H - 44, KURNOOL - 518 218, A.P. INDIA.
E-mail : principalkvsrip@gmail.com www.drkvsrip.ac.in

Principal / Correspondent

Date : .

From
Principal,
Dr.K.V. Subba Reddy Institute of Pharmacy,
Dupadu.

To,
R.Naganjaneyulu,
Associate Professor,
Dr .K.V Subba Reddy Institute Of Pharmacy
Dupadu,
Kurnool.

Sub: Permission for Plantation Program

With respect to subject cited it is to inform you to conduct tree plantation programme at Jaganatha gattu, kurnool on 22-10-2021 as a part of Field work for students of B.Pharm & Pharm. D of our college.

Sr. K. V. S. R.
PRINCIPAL
Dr. K.V.S.R. Institute of Pharmacy
Opp: Dupadu R.S. N.H.-44,
KURNOOL-518218 (A.P.)

OFFICE OF THE DIRECTOR OF MEDICAL EDUCATION, AP, VIJAYAWADA

Rc.No.1595673/ME/2021

Dt: 31/12/2021

Sub: DME,A.P.-ME-K.V.Subba Reddy Institute of Pharmacy, Kurnool-
- clinical training for Pharma.D students at GGH, Kurnool- Renewal of
MOU -Reg.

Ref: -Rc.No.1778/E5/2021, Dt:07-09-2021 of the Superintendent (FAC), GGH, Kurnool

<<<>>>

The attention of the Superintendent, Govt. General Hospital, Kurnool is invited to the reference cited above, he is permitted to enter the Memorandum of Understanding (MOU) with the Principal, K.V.Subba Reddy Institute of Pharmacy, Kurnool duly following the conditions of G.O.Ms.No.398 HM&FW (E1) Department, Dt:15.11.2008.

DR M RAGHAVENDRA

RAO, DIR(MRR), O/o DIRECTOR-DME

Director of Medical Education

Signed by Dr M

Raghavendra Rao

Date: 31-12-2021 15:22:02

Reason: Approved

To

The Superintendent, Govt. General Hospital, Kurnool

Copy to the Principal, K.V.Subba Reddy Institute of Pharmacy, Kurnool

Copy to file.

Rc.No.428/E5/2022 dt. -03-2022


OFFICE OF THE SUPERINTENDENT
GOVT.GENERAL HOSPITAL: KURNOOL


Sub: -GGH; Kurnool – Clinical Training to the 2nd, 3rd, 4th, 5th & 6th –year students of Pharma D Course of K.V.S.R. Institute of Pharmacy, Kurnool – in the Hospital for the Academic Year 2021-2022.

- Ref: -1. MOU dt. 05.10.2015 between the Supt. G.G.H. Kurnool and the principal, KVSR Institute of Pharmacy, Kurnool.
2. Rc. No. 1595673/ME/2021 dt. 31.12.2021 of the DME (AP), Vijayawada.
3. G.O.Ms.No. 398HM&FW (E1) Dept dt. 15-11-2008
4. Office Note approved dt. 08/01/2018 of the Superintendent, Govt. General Hospital, Kurnool.
5. Lr. dt. 17-03-2022 of the Principal, KVSR Inst. of Pharmacy, Kurnool.

--

With reference to the subject cited permission is hereby accorded to undergo the Clinical Training to the 2nd -Year, 3rd -year 4th -year 5th- year and 6th – year Pharma D. Students of Dr. K. V. Subba Reddy Institute of Pharmacy, Kurnool for the year 2021-2022 in the Hospital and the allocated room identified on the Southern side of the Medical Record Section of the Hospital, has been continued to establish Pharmacy Practice Department for the conduct of Pharm. D Programmes, as part of the clinical training to their students in the Specialty departments of 1. Medicine, 2.Surgery, 3.Pediatrics, 4. Ost.& Gynaecy, 5.Psychiatry, 6.D.V.L. and 7. Orthopedics of this Hospital.


SUPERINTENDENT (FAC)



To

- 1) The Principal, KVSR Institute of Pharmacy, Opp Dupadu Rly.Station, H.H.7, Kurnool 518 218

Copy to the Civil Surgeon RMO I/c, G.G.H; Kurnool for information.

Copy to Nursing Superintendent; Assistant .RMO, GGH; Kurnool.

,, Pharmacy Supervisor through the Medl. Officer (Stores) I/c GGH,Kurnool.

, prof. &HOD of 1. Medicine, 2. Surgery, 3. Obst.Gyn. 4. Pediatric; 5. Psychiatry,

6. DVL and 7. Orthopedics, for information.

,, Principal , Kurnool Medical College, Kurnool for information.Copy submitted to the

2. Collector and Dist. Magistrate & Chairman, Hospital, Development Society, Kurnool and

2. Director of Medical Education (AP), Vijayawada, for kind information.



Dr. K.V. Subba Reddy Institute of Pharmacy

(Approved by AICTE, P.C.I. New Delhi & Permanently Affiliated to JNTUA Anantapuramu,
MOU with Government General Hospital & KMC, Kurnool)

Opp : Dupadu R.S., N.H - 44, KURNOOL - 518 218, A.P. INDIA.

E-mail : principalkvsrip@gmail.com www.drkvsrip.in

Principal / Correspondent

Date :

Ref: Pharm D/ER/CP 2021-22/GGH/22

To,
The Superintendent,
Government General Hospital,
Kurnool-518002.
Respected Sir,

Sub:- Dr. K. V. Subba Reddy Institute of Pharmacy, Kurnool- **Permission for Clinical Practice to Pharm. D Students**- Requested - Regarding .

Ref: Rc. No. 1778/E5/2021 Office of the Director of Medical Education, Andhra Pradesh Dated :07/09/2021.

With reference to the subject cited, I here with submit the details of students who are studying Pharm. D 2nd, 3rd, 4th, 5th and 6th year in our College during the Academic year 2021-2022. Necessary Permission has been obtained from the Director of Medical Education, A.P for the use Government General Hospital Kurnool for Clinical Practice of our Pharm.D Students. Required fee is paid in the form of Demand Draft.

Hence, I request you to kindly approve the allotted **schedules** for our students at the earliest.


Year of study	2 nd year	3 rd year	4 th year	5 th Year	6 th Year
No. of Students	31	27	31	29	29
Fee per student (Rs)	1,000	1,000	1,000	1,000	25,000
Total Fee (Rs)	31,000	27,000	31,000	29,000	7,25,000
Grand Total (Rs)	8,43,000/-				

Yours Faithfully,

Principal


Encl: 1. Demand Draft for Rs. 8,43,000 /- bearing no: dated :16/03/2022
2. List of Students

HOSPITAL COPY


TAPAL CLERK
Govt. Gen Hospit
KURNOOL

PRINCIPAL
Dr. K.V.S.R. Institute of Pharmacy
Opp. Dupadu R.S. N.H-7,
KURNOOL-518218 (A.P.)

Cell : 09704 333 789



Dr. K.V. Subba Reddy Institute of Pharmacy

(Approved by AICTE, P.C.I New Delhi & Affiliated to JNTUA Anantapuramu,
MoU with Government General Hospital & KMC, Kurnool)

Opp. Dupadu Railway Station, Lakshmipuram (Po), N.H - 44, KURNOOL - 518 218, A.P. INDIA.

Website : www.drkvsrip.in

e-mail : principalkvsrip@gmail.com

Date : 12.1.2021

Lr No: KVSP/Pharm.D/C.P/2021-22/01

To,

The Director of Medical Education,
Andhra Pradesh,
Old Government Hospital Premises,
Hanumanpeta,
VIJAYAWADA.

(Through Superintendent,
Government General Hospital,
Kurnool.)

Respected Sir,

Sub: Dr K V Subba Reddy Inst of Pharmacy. Kurnool – Renewal of MOU with G.G.H .Kurnool for
Conduct of Clinical Practice -Grant of Permission –Requested - Regarding.

Ref: 1. Rc No: 28333/ME/2017-20 dt 25/02/2020 of the DME (AP) Vijayawada .

2. MOU entered between the Supdt.GGH; Kurnool and the principal, Dr K V Subba Reddy
Inst of Pharmacy, Lakshmipuram (post) Kurnool -518218.

With reference to the Subject cited, I here with submit that we have utilized the services of
G.G.H, Kurnool for conduct of Clinical Practice during the years 2016-17 to 2020-2021 for the Pharma.D
students of our College with the Cooperation of G.G.H staff. Now, I request you Sir to kindly grant
renewal of Permission for the Academic Year 2021-2022 for the Conduct of clinical practice for the II, III,
IV, V and VI years of Pharm.D Course of our College.

Encl:


Copy of MOU

Copy Submitted to


The Superintendent,
Government General Hospital,
Kurnool.



Yours Faithfully


PRINCIPAL

Dr. K.V.S.R. Institute of Pharmacy
Opp Dupadu R.S. N.H-7,
Kurnool - 518218 (A.P.)


TAPAL CLERK
Govt. Gen Hospital
KURNOOL



ఆంధ్రప్రదేశ్ ఆంధ్ర ప్రదేశ్ ANDHRA PRADESH

10500278
BT 628024

Sl. No. 7807

Date: 1-10-2015

Rs. 100

Sold to
For whom

K.V. సబ్బారెడ్డి & స/స కనారెడ్డి కళ్యాణ
K.V. సబ్బారెడ్డి ఛార్జి రెడ్డి కళ్యాణ

A. VENKATESWARLU
Lic. and Pharm. Vendor
L. No. 13-21-1-1999
Ph. No. 13021 0012013 to 2015
H.No. 5915, Part, Kurnool - 513001
Cell : 9822036834

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding is made on 05 Day October month 2015 Year

between

Government General Hospital, Budhawarpet, kurnool Which is represented by its Superintendent herein named as party one

and

Dr.K.V.Subba Reddy Institute of Pharmacy, Opp. Dupadu Railway Station, N.H.-7, Laxmipuram Post , Kallur Mandal , Kurnool and affiliating to Jawaharlal Nehru Technological University Anantapur represented by its Principal herein named as party two

The parties hitherto agree as follows:

1. Party one declares that Government General Hospital, Budhawarpet, kurnool is a 1050 bedded hospital, with a minimum of 120 beds for General Medicine Department.
2. Party one agrees to provide to party two the minimum space necessary of 1200 square feet in the hospital building to establish Pharmacy Practice department for the conduct of Pharm.D programs
3. Party one agrees to provide preceptors required to train the Pharm.D students.
4. Party one agrees that, it will not enter into similar agreement with any other Pharmacy institution/s or department/s offering or intend to offer Pharm.D programs.

Signature
12/10/2015
Govl. General Hospital
KURNOOL

Signature
PRINCIPAL
Dr. K.V.S.R. Inst. of Pharmacy,
Opp Dupadu R.S., N.H-7
KURNOOL - 518218 (A.P.)

PRINCIPAL
Dr. K.V.S.R. Institute of Pharmacy
Opp. Dupadu R.S. N.H-7.

Dr. K. V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU KURNOOL, PHARM D II YR 2021-2022
(M.O.U WITH G.G.H KURNOOL)

ROLL NO	NAME OF STUDENT	JAN-FEB (2022)	MARCH-APRIL (2022)	MAY-JUNE (2022)	JULY (2022)	AUGUST (2022)	SEPTEMBER (2022)	OCTOBER (2022)
20ERIT0002	DADIPINENI LEE LAVATHI							
20ERIT0003	DEVARAKONDA GAMANASREE							
20ERIT0004	DUPATI MAHA AISHWARYA	PAEDIATRICS (CHMW-1,2)	MM-7	MM-2	PATIENT COUNSELLING	MM-1	PAEDIATRICS (CHMW-3,4)	MM-3
20ERIT0005	GIGGULA SUCHARITHA							
20ERIT0006	GURRAM KAVYA							
20ERIT0007	HEBBARE SRAVANI BAI							
20ERIT0008	JINKA LAVANYA							
20ERIT0009	KALLUR SAI SIRESHA	MM-3	PAEDIATRICS (CHMW-1,2)	MM-7	MM-2	PATIENT COUNSELLING	MM-1	PAEDIATRICS (CHMW-3,4)
20ERIT0010	KAMALAPURAM SUPRAJA BAI							
20ERIT0011	KOTHAMASUM HIMA BINDU							
20ERIT0012	MADDALA BHAVYASREE							
20ERIT0013	MAMIDI HEMALATHA							
20ERIT0014	MEDIGA SUMALATHA	PAEDIATRICS (CHMW-3,4)	MM-3	PAEDIATRICS (CHMW-1,2)	MM-7	MM-2	PATIENT COUNSELLING	MM-1
20ERIT0015	MENUGA CHITRA							
20ERIT0016	M.MERCY AMULYA							
20ERIT0017	SUVARNA SRAVANI							
20ERIT0018	VAVILALA ARCHANA							
20ERIT0019	VISANAKARRA TRIYENI	MM-1	PAEDIATRICS (CHMW-3,4)	MM-3	PAEDIATRICS (CHMW-1,2)	MM-7	MM-2	PATIENT COUNSELLING
20ERIT0020	BOGYAM MANASA							
20ERIT0021	EDDUPENTA SUMANJALI							
20ERIT0022	EPPALA CHARITHA							
20ERIT0023	GENIKALA NAGA SUREKHA							
20ERIT0024	GUNDA KIRITI							
20ERIT0025	SHAIK IRSHAD NUFESHUN	PATIENT COUNSELLING	MM-1	PAEDIATRICS (CHMW-3,4)	MM-3	PAEDIATRICS (CHMW-1,2)	MM-7	MM-2
20ERIT0026	VANGALA SAMYUKTHA							
20ERIT0027	MOLLA KIFAYATHULLA							
20ERIT0028	K.S.PRADHIVUMNA							
20ERIT0029	SYED ABRAR AHMED							
20ERIT0030	SHAIK NASIR AHMAD	MM-2	PATIENT COUNSELLING	MM-1	PAEDIATRICS (CHMW-3,4)	MM-3	PAEDIATRICS (CHMW-1,2)	MM-7
20ERIT0031	VEMULURI VIJAY TEJA							
20ERIT0032	SHAIK KHALID							

PRINCIPAL
Dr. K. V. SUBBA REDDY INSTITUTE OF PHARMACY
KURNOOL

SUPERINTENDENT
GOVERNMENT GENERAL HOSPITAL
KURNOOL

Dr. K.V.S.R. Institute of Pharmacy
Opp. Dupadu R.S. N.H-7,
KURNOOL-518218 (A.P.)

[Signature]
22/1/2022

Dr. K. V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU KURNOOL (M.O.U WITH G.G.H KURNOOL) III rd YEAR 2021-2022

ROLL NUMBERS	NAMES OF STUDENTS	Aug-Sept (2021)	Oct-Nov	Dec-Jan(2022)	Feb-March	April-May	June
19ER1T0002	Alefiya kotawala						
19ER1T0003	A.Keerthi						
19ER1T0004	B.Sowjanya	MM-7	DVL	PATIENT COUNSELING	MM-3	MM-1	MM-2
19ER1T0005	B.Aswini Bai						
19ER1T0006	C.Sushma						
19ER1T0009	G.Mounika						
19ER1T0010	G.Naga vinugna						
19ER1T0012	K. Meghana	MM-2	MM-7	DVL	PATIENT COUNSELING	MM-3	MM-1
19ER1T0013	P. Naga Sruthi						
19ER1T0014	Shaik Rizwana						
19ER1T0018	B. Mounika						
19ER1T0024	P. Sudha	MM-1	MM-2	MM-7	DVL	PATIENT COUNSELING	MM-3
19ER1T0025	S.Navya Sree						
19ER1T0026	T. Khasid						
19ER1T0028	Valmiki Venkateshwari						
19ER1T0029	Vangala Naga divya	MM-3	MM-1	MM-2	MM-7	DVL	PATIENT COUNSELING
19ER1T0007	C. Mehaboob Desai						
19ER1T0001	A. Dilip Kumar						
19ER1T0011	K.Sai Chaitanya						
19ER1T0015	V. Vamsi Krishna						
19ER1T0016	A. Sai Kumar Reddy	PATIENT COUNSELING	MM-3	MM-1	MM-2	MM-7	DVL
19ER1T0017	B. Venkatesh						
19ER1T0019	K. Veera Reddy						
19ER1T0020	K. Satyanarayana charan						
19ER1T0021	M. Hanumantha						
19ER1T0023	P. Siva Gangadhar	DVL	PATIENT COUNSELING	MM-3	MM-1	MM-2	MM-7
19ER1T0027	T. Bhanu Prakash						

PRINCIPAL
Dr. K. V. SUBBA REDDY INSTITUTE OF PHARMACY
KURNOOL

PRINCIPAL

Dr. K.V.S.R. Institute of Pharmacy
Opp. Dupadu R.S. N.H-7,
KURNOOL-518218 (A.P.)

23/1/2022
SUPERINTENDENT
GOVERNMENT GENERAL HOSPITAL
KURNOOL

Dr. K. V. SUBBA REDDY INSITITUE OF PHARMACY , DUPADU KURNOOL (M.O.U WITH G.G.H KURNOOL) 2021-2022
PHARM D IV YEAR

ROLL NUMBERS	NAMES OF STUDENTS	Aug-Sept (2021)	Oct-Nov	Dec-Jan(2022)	Feb-March	April-May	June
18ER1T0001	B.RAMADEVI	MM-1	MM-7	MM-3 MM-4	PAEDIATRICS	PSYCHIATRIC	MM-2
18ER1T0002	G.SAI VILASHINI						
18ER1T0003	E.LIKHITA						
18ER1T0004	J.DIVYASREE						
18ER1T0005	J.HEMALATHA						
18ER1T0007	M.MANIPRASANNA	MM-2	MM-1	MM-7	MM-3 MM-4	PAEDIATRICS	PSYCHIATRIC
18ER1T0008	M.RADHIKA						
18ER1T0010	P.ASMA						
18ER1T0011	S.TAHURA BATUL						
18ER1T0013	S.ZUWERIYA SULTANA						
18ER1T0014	D.DURGA PAVITRA	PSYCHIATRIC	MM-2	MM-1	MM-7	MM-3 MM-4	PAEDIATRICS
18ER1T0015	S.VANI						
18ER1T0016	T.JAHNAVI						
18ER1T0017	U.JOSHITHA						
18ER1T0018	V.TEJASWINI						
18ER1T0019	V.MALLESHWARI	PAEDIATRICS	PSYCHIATRIC	MM-2	MM-1	MM-7	MM-3 MM-4
18ER1T0021	J.ZUHA KHANAM						
18ER1T0022	K.KEERTHANA						
18ER1T0023	K.DIVYA SIRISHA						
18ER1T0025	S.ASMA PARVEEN						
18ER1T0026	E.ROHINI VADANA	MM-3 MM-4	PAEDIATRICS	PSYCHIATRIC	MM-2	MM-1	MM-7
18ER1T0029	S.SANA AFREEN						
18ER1T0030	S.SANA AFREEN						
18ER1T0011	S.BABA ARSHID						
18ER1T0006	K.SHANMUKA GANESH						
18ER1T0009	M.SUJAN DORA	MM-7	MM-3 MM-4	PAEDIATRICS	PSYCHIATRIC	MM-2	MM-1
18ER1T0020	I.SAIKIRAN						
18ER1T0024	M.PRANEETH PREMPAUL						
18ER1T0027	P.ANWAR BASHA						
18ER1T0028	R.VIJAY VIKAS						
17ER1T0026	S.NEHAL						

PRINCIPAL
Dr.K.V SUBBA REDDY INSTITUE OF PHARMACY
KURNOOL

PRINCIPAL
Dr. K.V.S.R. Institute of Pharmico
Opp. Dupadu R.S. N.H-7,
KURNOOL-518218 (A.P.)

SUPERINTENDENT
GOVERNMENT GENERAL HOSPITAL
KURNOOL

23/7/22

Dr. K. V. Subba Reddy Institute of Pharmacy, Dupadu Kurnool (M.O.U WITH G.G.H KURNOOL)

PHARM D CLERIK SHIP HOSPITAL POSTINGS 2021-2022)

Roll No	Names	Aug-Sept (2021)	Oct-Nov	Dec-Jan (2022)	Feb-March	April	May
17ERIT0001	B. SOWJANYA	General surgery	Pediatrics	MM-1 MM-2	DVL	Psychiatry	MM-7
17ERIT0002	D SANDYA						
17ERIT0003	D. CHETHANA						
17ERIT0004	D.SHAILAJA						
17ERIT0005	K. SUPRAJA						
17ERIT0006	K. LAKSHMI CHARITHA	MM-7	General surgery	Pediatrics	MM-1 MM-2	DVL	Psychiatry
17ERIT0007	K.BHAVANI						
17ERIT0008	M. PRIYANKA						
17ERIT0009	M. MAMATHA						
17ERIT0010	N. VIJAYA						
17ERIT0011	N. NAVYASREE	Psychiatry	MM-7	General surgery	Pediatrics	MM-1 MM-2	DVL
17ERIT0012	S RUKSAR SAMREEN						
17ERIT0013	S. SUHASINI						
17ERIT0015	S. SHAFIYA TABASSUM						
17ERIT0016	SHAIK WASIMA NASREEN						
17ERIT0017	AMBATI PAVITRA	DVL	Psychiatry	MM-7	General surgery	Pediatrics	MM-1 MM-2
17ERIT0018	G. LEOHON REBEKHA						
17ERIT0019	J PAVITRA						
17ERIT0021	M. VAISHNAVI						
17ERIT0022	N.SHINY SUSAN						
17ERIT0023	P. DIVYA	MM-1 MM-2	DVL	Psychiatry	MM-7	General surgery	Pediatrics
17ERIT0025	RUMSHA RUKSAR						
17ERIT0027	SHAIK THASLEEM						
17ERIT0028	T. YAMMINI						
17ERIT0029	V.SAMYUKTHA						
17ERIT0014	S. VISWANATH REDDY	Pediatrics	MM-1 MM-2	DVL	Psychiatry	MM-7	General surgery
17ERIT0020	K.LAL REDDY						
17ERIT0024	R. NEERAJ						
17ERIT0030	Y KARTHIK KUMAR						
16Y01T0023	SHOAIB ABDUR RAQUEEB						

PRINCIPAL

Dr.K.V SUBBA REDDY INSTITUE OF PHARMACY
KURNOOL

PRINCIPAL


Dr. K.V.S.R. Institute of Pharma
Opp. Dupadu R.S. N.H-7,
KURNOOL-518218 (A.P.)

SUPERINTENDENT


GOVERNAMENT GENERAL HOSPITAL
KURNOOL


Dr. K. V. SUBBA REDDY INSITITUE OF PHARMACY , DUPADU KURNOOL (M.O.U WITH G.G.H KURNOOL) INTERNSHIP 2021-2022 YEAR

ROLL NUMBERS	NAME OF THE STUDENT	JUNE (15/06/2021)-JULY	AUGUST- SEPTEMBER	OCTOBER- NOVEMBER	DECEMBER- JANUARY 2022)	FEBURARY-MARCH	APRIL-JUNE (14/06/2022)
16ER1T0007	G.NAVEEN BABU	PSYCHIATRIC	PEADIATRICS	GENERAL SURGERY	MM-7	MM-8	FM-1
16ER1T0008	ASAD ALI KHAN						
16ER1T0010	M.RAMANJANEYULU						
16ER1T0011	M.RAM SUNIL						
16ER1T0017	D.YAKUB BASHA	FM-7 FM-8	PSYCHIATRIC	PEADIATRICS	GENERAL SURGERY	MM-7	MM-2
16ER1T0003	P.JAVEED						
16ER1T0006	S.MANIKANTA						
16ER1T0020	S.LOKESH ROYAL						
16ER1T0023	S.SUBBA REDDY	MM-8	FM-7 FM-8	PSYCHIATRIC	PEADIATRICS	GENERAL SURGERY	MM-7
16ER1T0004	C.KEERTHI						
16ER1T0013	M.SAI DEEPIKA						
16ER1T0029	L.SWETHA MADHURIMA						
16ER1T0015	D.SHARON ROSE	MM-7	MM-8	FM-7 FM-8	PSYCHIATRIC	PEADIATRICS	GENERAL SURGERY
16ER1T0016	M.V.NAGA VASAVI LATHA						
16ER1T0026	L. Grace						
16ER1T0027	R.MANASA						
16ER1T0028	S.SHABANA TASAJEN	GENERAL SURGERY	MM-7	MM-8	FM-7 FM-8	PSYCHIATRIC	PEADIATRICS
16ER1T0014	S.SUMERA IRHAM						
16ER1T0030	D.JAYAROOPIA VANI						
16ER1T0018	B.BHAVANA						
16ER1T0019	SRI KRISHINA JYOTIKA	PEADIATRICS	GENERAL SURGERY	MM-7	MM-8	FM-7 FM-8	PSYCHIATRIC
16ER1T0021	M.PRIYANJALI						
16ER1T0024	I.VAISHNAVI						
16ER1T0025	V.HARI SUSHUMA						
16ER1T0001	B.AKHILA	PEADIATRICS	GENERAL SURGERY	MM-7	MM-8	FM-7 FM-8	PSYCHIATRIC
16ER1T0002	M.AKSHITHA						
16ER1T0005	LASYA						
16ER1T0009	P.PREMA LATHA						
16ER1T0012	SADIYA SAMREEN						


 PRINCIPAL
 Dr.K.V SUBBA REDDY INSITUE OF PHARMACY
 KURNOOL

PRINCIPAL
 Dr. K.V.S.R. Institute of Pharmac.
 Opp. Dupadu R.S. N.H-7.
 KURNOOL-518218 (A.P)


 SUPERINTENDENT
 GOVERNMENT GENERAL HOSPITAL
 KURNOOL


 22/7/2022





Shot on OnePlus
By Chēthū





MEMORANDUM OF UNDERSTANDING (MOU)

Between

**PELCOAT FORMULATIONS,
Survey no- 13, Kucharam Village,
Toopran Mandal, Medak Dist.
Hyderabad - 502336, Telangana, India
And**

**K. V. SUBBA REDDY INSTITUTE OF PHARMACY
Opp: Dupadu RS, N.H-44, Lakshmi Puram (Post),
Kurnool Dt.**

For

**Facilitating collaborative research & development in
The areas of new drug discovery,
Formulation development, clinical studies and
Industry academia interaction for teaching and research**



This **MEMORANDUM OF UNDERSTANDING** (“**MOU**”) is executed on this 15 day of JULY, 2017 at KURNOOL by and between:

1. **PELCOAT FORMULATIONS**, a company incorporated and registered under the [Indian] Companies Act, 1956 and having its registered office at Survey no- 13, Toopran Mandal, Kucharam Village, Hyderabad, Telangana 502336 (hereinafter referred to as “**PELCOAT**”, which expression shall, unless repugnant to the meaning and context thereof, be deemed to include its successors and permitted assigns), of the **FIRST PART**; and
2. **Dr. K. V. Subba Reddy Institute of Pharmacy**, an affiliated college of Jawaharlal Nehru Technological University Anantapur, Anantapuramu and having its principal office at Opp. Dupadu RS, NH-44, Lakshmipuram (Post), Kurnool-518218 (hereinafter referred to as “**Dr. KVSP**”, which expression shall, unless repugnant to the meaning and context thereof, be deemed to include its successors and permitted assigns), of the **SECOND AND THE LAST PART**.

PELCOAT and **Dr. KVSP** may hereinafter collectively be referred to as the “**Parties**” and individually each of them may be referred to as a “**Party**”.

WHEREAS:

- A. PELCOAT is engaged in the business of developing, manufacturing and distributing pharmaceutical products for pharmaceutical companies and its business includes *inter alia*:
- (a) manufacturing and/ or distribution of drugs at various dosage strengths including therapeutically equivalent ANDA based products and other products on a case-by-case basis;
 - (b) distribution of various drugs and marketing and/or licensing more than 60 (sixty) prescription drug product families in the United States of America;
 - (c) modified release of oral solid dosage forms as well as non-oral dosage forms of drugs such as nasal sprays, dry powder inhalers, patches and other alternative drug delivery platforms; and
 - (d) exchanging new scientific information and knowledge, transferring new technologies, exchanging students, scientists and technicians and commercializing products manufactured and/ or distributed by it through collaborative research;

(hereinafter collectively referred to as the “**Business**”). The generic-drug portfolio of PELCOAT consists of numerous products across a wide range of therapeutic areas that are the therapeutic equivalent of the brand-name pharmaceuticals.¹



¹ PELCOAT to confirm that this accurately reflects its business activities.

- B. Dr. KVSP was established in the year 2007, with the object of imparting quality pharmacy education in India at graduate, postgraduate and doctoral levels. Dr. KVSP has the following mission and vision:

(a) Mission Statement

To impart knowledge, develop skills and competencies in students in pharmaceutical sciences and pharmacy practice

To develop and advance the knowledge, attitude and skills of pharmacists and faculty member who can provide comprehensive pharmaceutical care to patients, improve patient outcomes, and meet societal needs for safe and effective drug therapy.

To develop, promote and nurture research activities pursuing advances in pharmaceutical sciences and pharmacy practice. Translating research into healthcare practice is a cornerstone of our mission.

(b) Vision Statement

To be a leader in pharmaceutical sciences & pharmacy practice education, research and continuous professional development for pharmacists with the ultimate aim of providing competent patient care and drug development to national and international communities.

- C. The Parties are discussing the possibilities of arriving at an understanding for:

- (a) cooperation and joint research in (i) the areas of drug discovery, development and research leading to the award of Ph.D. degree as per the rules of the Jawaharlal Nehru Technological University Anantapur and as may be provided in the Ph.D. regulations of the Jawaharlal Nehru Technological University Anantapur; and (ii) such other areas as may be mutually agreed upon in writing between the Parties from time to time;
- (b) Mutually engaging in bidding to private and public organizations for various scientific proposals and participating in various seminars or conferences as a single service provider. This understanding would include:
- (i) faculty exchange programs between members of the Parties and scientists for closer interactions; and
- (ii) Sponsorship by PELCOAT, of identified research projects to be undertaken by Ph. D. / M. Pharm candidates of the Dr. KVSP, which would also involve periodical meetings of the relevant students and supervisors, subject to mutual consultation of both the Parties.

The detailed modalities of the working of individual projects shall be arrived at after mutual discussions between the Parties and documented separately as project specific agreement / contracts before taking up the project;



(Collectively referred to as the “**Proposed Transaction**”).

- D. The Parties are entering into and executing this MOU, to set out their mutual understanding in relation to the Proposed Transaction. Each of the Parties understand that, unless specifically provided herein, this MOU is indicative of the principal terms of the Proposed Transaction and that this MOU does not constitute any commitment on part of either Party to consummate the Proposed Transaction.

NOW THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth in this MOU and other consideration, the sufficiency and adequacy of which is hereby acknowledged, the Parties agree as follows:

1. DEFINITIVE AGREEMENTS


The Parties acknowledge that their understanding in relation to the Proposed Transaction, as contemplated in this MOU, shall be subject to execution of definitive agreements for consummation of the Proposed Transaction between the Parties (“**Definitive Agreements**”). It is hereby clarified that the Definitive Agreements shall encapsulate the broad terms contained herein and may be supplemented by work plans to be developed jointly by the Parties, which would more specifically detail the activities to be carried out by the Parties under their cooperative programme and the envisaged contribution of each Party in respect thereof.²

2. OBLIGATIONS OF THE PARTIES

The Parties agree that the:

- (a) results of their research data which are collected, compiled and evaluated shall be shared and mutually exchanged by the Parties and their research findings in relation to areas identified by them will be published in public interest. However, Dr. KVSP shall hold complete unfettered editorial rights with respect to the findings that are to be published by the Parties, which rights shall be exercised by Dr. KVSP to safeguard the mutual interests of the Parties and to protect any intellectual property rights generated through such work;
- (b) instruments and equipment’s available at their respective facilities shall be shared mutually by the Parties to facilitate the objective intended to be achieved by the Proposed Transaction;
- (c) results of the collaborative research of the Parties may, subject to the consent of Dr. KVSP, be used for experimental and clinical trials and demonstrations, with active participation of the Parties;
- (d) scientific representatives of the Parties shall conduct periodical meetings (minimum half yearly) at such premises as may be mutually identified by the Parties, to discuss their progress on the objectives sought to be achieved by the Proposed Transaction;

² We would recommend that independent agreement be executed between the Parties for setting out their understanding in respect of the Proposed Transaction e.g. a separate research and development agreement should be entered into. This MOU has accordingly been suitably modified.



- (e) Parties may nominate members of their respective staff to work out the practical details of cooperation between the Parties and in general, to ensure proper and effective implementation of the Proposed Transaction. Such details, as agreed upon, will be confirmed by way of execution of the Definitive Agreements by the Parties.

3. TERM AND TERMINATION

This MOU will be in effect until execution of the Definitive Agreements by the Parties and may be terminated by the mutual written agreement of the Parties. Termination of this MOU shall however, not affect the binding obligations stated in Clause 4, Clause 6 (to the extent applicable), Clause 8.2 and Clause 10 of this MOU and the same shall be binding on the Parties.

Each of the Definitive Agreements shall be in effect initially for a period of 5 (five) years from the date of its execution and may be renewed subject to mutual written agreement of the Parties. Either Party may terminate a Definitive Agreement by written notification thereof to the other Party. Such notice must be received by the other Party at least 3 (three) months prior to the effective termination date of the relevant Definitive Agreement.

4. CONFIDENTIALITY

The Parties recognize that, by virtue of this MOU, they may be given and may have access to information relating to each Party, its affiliates, the Business and other proprietary information (“**Confidential Information**”) and accordingly undertake not to, without the prior written consent of the other Party, divulge and/ or communicate to any person, or use or exploit for any purpose whatsoever, any of the Confidential Information that any Party may receive or obtain as a result of entering into this MOU, and shall use reasonable endeavours to prevent their respective officers, employees or agents, if any, from doing so. These obligations and restrictions contained herein shall not apply to:

- (a) the extent that the Confidential Information is in the public domain other than by breach of this MOU;
- (b) the extent that the Confidential Information is required to be disclosed by any applicable law or any applicable regulatory requirements or by any regulatory body to whose jurisdiction the relevant Party is subject or with whose instructions it is customary to comply under notice to the other Party;
- (c) in so far as it is disclosed to the employees, directors or professional advisers, lenders, investors of any Party, provided that such Party shall procure that such persons treat the Confidential Information as confidential;
- (d) the extent that any of the Confidential Information is later acquired by a Party from a source not obligated to any other Party hereto, or its affiliates, to keep the Confidential Information confidential;
- (e) the extent that any of the Confidential Information is required by a Party for the purposes of enforcing or protecting or promoting its rights pursuant to this MOU, or for the purposes of performing the provisions of this MOU or performing the duties and other obligations of this MOU;



- (f) the extent that any of the Confidential Information was previously known or already in the lawful possession of a Party, prior to disclosure by the other Party; and
- (g) The extent that any information, similar to the Confidential Information, was independently developed by a Party without reference to any Confidential Information furnished by the other Party.

5. INDEMNITY

The Definitive Agreements shall contain mutual indemnity provisions for each Party (“**Indemnifying Party**”) to indemnify and hold harmless the other Party (“**Indemnified Party**”), from and against any and all liabilities, losses, damages, costs, claims, actions, proceedings, judgments, settlements, expenses or the like which may be suffered or incurred directly, but not consequentially, by the Indemnified Party as a result of:

- (a) any misrepresentation or breach of any representation or warranty made by the Indemnifying Party in the Definitive Agreement; or
- (b) breach of any covenant or obligation or agreement or undertaking contained in the Definitive Agreement by the Indemnifying Party; or
- (c) the negligent acts or omissions of Indemnifying Party or its agents or employees, pertaining to the activities to be carried by the Indemnifying Party pursuant to its obligations under the Definitive Agreement; provided however, that the Indemnifying Party shall not hold the Indemnified Party harmless from claims arising out of the negligence or wilful malfeasance of the Indemnified Party or its officers, agents, or employees or due to the negligent failure of the Indemnified Party to comply with any applicable governmental requirements or to adhere to the terms of the research as specified in the Definitive Agreement.

6. INTELLECTUAL PROPERTY

6.1. For the purposes of this Clause:

“**Invention**” shall mean any discovery, concept, or idea (whether or not patentable, and whether or not patent protection has been applied for or granted), made during the conduct of the study/ research relating to the Proposed Transaction during the tenure of the Definitive Agreements, and arising directly from the performance of the study/ research relating to the Proposed Transaction under the Definitive Agreements, including but not limited to processes, methods, software, tangible research products, formulas and techniques, improvements thereto, and know-how related thereto; and

- (a) “**Intellectual Property**” shall mean all intellectual and industrial property and all rights therein including, without limiting the generality of the foregoing, all Inventions, improvements, developments, discoveries, proprietary information, trademarks, trade mark applications, trade names, websites, internet domain names, logos, slogans, know-how, trade secrets, processes, designs (whether or not registerable and whether or not design rights subsist in them), and works in which copy-right may subsist (including computer software and preparatory and design materials therefore).



- 6.2. The Parties agree that the existing inventions and technologies of each of the Parties, as on date of execution of this MOU, are their separate property respectively and are not affected by this MOU and neither Party shall have any claims to or rights in such existing inventions and technologies of the other Party.
- 6.3. Further, in the event that any new Intellectual Property is generated as a result of performance of the obligations of the Parties under the Definitive Agreements (including any Intellectual Property generated as a result of any project and/ or joint research projects undertaken by the Parties under the Definitive Agreements), PELCOAT shall take all responsibility for filing and processing of such collaborative Intellectual Property (including bearing of all expenses for any pre-grant or post-grant oppositions relating thereto). The Parties agree that all Intellectual Property jointly developed or acquired by them under the Definitive Agreements, shall be the sole property of PELCOAT.
- 6.4. Dr. KVSP acknowledges and agrees that all Inventions made, written, discussed, developed, secured, obtained or learned during the tenure of the Definitive Agreements shall be the sole property of PELCOAT including without limitation, all domestic and foreign patent rights, rights of registration or other protection under the copyright laws, or other rights, pertaining to the Inventions. Dr. KVSP further agrees that all services, products and Inventions that directly or indirectly result from its engagement with PELCOAT shall be deemed to have arisen out of the course of the project/ research for which this MOU/ the Definitive Agreements are executed and accordingly, all rights associated therewith shall vest in PELCOAT.
- 6.5. Dr. KVSP agrees that all applications for registration of any Intellectual Properties developed under the Definitive Agreements, shall be made in the name of PELCOAT and shall be made by PELCOAT only and Dr. KVSP shall provide all such information and assistance as may be deemed necessary in this regard to PELCOAT.
- 6.6. The Parties will maintain confidentiality of all Intellectual Properties developed by any of them under the Definitive Agreement and shall not use the information in relation to such Intellectual Properties for any purpose other than those authorized in writing by the owner of Intellectual Property. However, wherever PELCOAT 's services are employed for patent filling, sealing, protection know-how developed, Dr. KVSP shall automatically assign the know-how to PELCOAT on a non-exclusive basis, the financial reimbursement for this assignment being the cost of the company assistance as above and the financial charges as mentioned in clause 6. Additionally, a lumpsum technology transfer charge to Dr. KVSP may be considered on a case-to-case basis.³

7. DISPUTE RESOLUTION UNDER THE DEFINITIVE AGREEMENTS

- 7.1. The Definitive Agreements shall be governed and construed in accordance with the laws of India and each Party under the Definitive Agreements shall irrevocably submit to the exclusive jurisdiction of the courts at Kurnool, India in respect of any disputes, legal action or proceedings arising out of the provisions of the Definitive Agreements.



³ The exact intent of the highlighted provision is not clear.

7.2. The Definitive Agreements shall also specify that:

- (a) any disputes or disagreements, arising out of, relating to or in connection with the terms and conditions of the Definitive Agreement or with respect to the validity, interpretation, implementation or alleged material breach of any provision thereof, whether during the subsistence of the Definitive Agreement or after its termination, shall be amicably settled between the Parties by mutual discussions between the senior management of the Parties;
- (b) in the event that such dispute has not been amicably settled within sixty (60) days, then such a question or dispute shall be referred to the arbitration in accordance with the provisions of the [Indian] Arbitration and Conciliation Act, 1996. The arbitration shall be conducted by a sole arbitrator to be appointed jointly by the Parties. In the event of the Parties not being able to concur on the appointment of a sole arbitrator, such sole arbitrator shall be appointed as per the provisions of the [Indian] Arbitration and Conciliation Act, 1996. The award of the arbitrator shall be final and binding on the Parties. The place of arbitration shall be Bangalore and the language to be used in the arbitral proceedings shall be English. The arbitrator's fee shall be borne equally by the Parties. All other costs and expenses of the arbitration shall be borne by the Parties as the arbitrator may award.

8. PUBLICATIONS

- 8.1. Subject to Clause 2(a) above, the Parties reserve the right to publish or otherwise make public the data resulting from the studies conducted pursuant to the terms of the Definitive Agreements. The Party wishing to publish or make public its findings, shall submit any such manuscript or release to the other Party for comment prior to its publication or release.
- 8.2. Neither Party shall use the name of the other Party or any of its employees in connection with any press release, advertisement, promotional literature or any other publicity matters relating to this MOU or the Proposed Transaction without the express prior written consent of the other Party.
- 8.3. Except as otherwise required by law or regulation, neither Party shall release or distribute any materials or information containing the name of the other Party or any of its employees without prior written approval by an authorized representative of the non-releasing Party.

9. RELATIONSHIP OF PARTIES

The Parties shall act in their independent capacities in the performance of their respective functions under this MOU and no Party shall be considered as an officer, agent or employee of the other Party.

10. GOVERNING LAW

This MOU shall be governed and construed in accordance with the laws of India and each Party hereby irrevocably submits to the exclusive jurisdiction of the courts at Kurnool, India in respect of any disputes, legal action or proceedings arising out of the binding provisions of this MOU.



11. EFFECTIVE DATE AND DURATION OF MOU

- This MOU shall be effective from the date of its approval by competent authorities at both ends.
- The duration of the MOU shall be for a period of 5 year from the effective date from **05 July, 2017 to 30 June 2022.**
- During its tenancy, the MOU may be extended or terminated by a prior notice of not less than three months by either party. However, termination of the MOU will not in any manner affect the interests of the students/faculty/scientists who have been admitted to pursue a programme under the MOU.
- Any clause or article of the MOU may be modified or amended by mutual agreement of **PELCOAT FORMULATIONS** and Dr. KVSrip.

12. NOTICES

Any notice and other communication provided for in this MOU shall be in writing and shall be first transmitted by facsimile/electronic transmission and then confirmed by courier service or registered mail, in the manner as elected by the Party giving such notice to the following addresses:

In the case of notices to PELCOAT:

Name : J Chenna Reddy
Address: : Sy no:13,Kucharam Village,Toopran Mandal,Medak Dist.
Phone: : 08454-250183
Fax No: : 08454-250182
Email: : md@pelcoat.com

In the case of notices to Dr. KVSP:

Name : Dr. G. Nagarajan
Signature :
Address: : Dupadu RS, N.H-44, Lakshmipuram (Post), Kurnool
Phone: : +919440282181, +919704333789
Fax No: : 08518-287618
Email: : principalkvsrip@gmail.com

All notices shall be deemed to have been validly given on (i) the day immediately after the date of transmission with confirmed answer back, if transmitted by facsimile/electronic transmission, or (ii) the day of receipt, if transmitted by courier or registered airmail. Any Party may, from time to time, change its address or representative for receipt of notices provided for in this MOU by giving to the other Parties not less than 30 (thirty) days prior written notice.



13. **AMENDMENT**

It is mutually agreed that this MOU may be amended or modified renewed by the mutual written consent of the Parties.

14. **SEVERABILITY**

The invalidity or unenforceability of any term or provision of this MOU shall not affect the validity or enforceability of any other term or provision hereof.

15. **ASSIGNMENT**

Neither this MOU nor the rights or obligations hereunder shall be assignable or otherwise transferred or subcontracted by either of the Parties without the prior written consent of the other Parties and any attempted assignment in violation of the terms hereof shall be void.

16. **COUNTERPARTS**

This MOU may be executed in counterparts and each counterpart shall, taken together, constitute one and the same instrument.


17. **NON-BINDING**

This MOU is intended as a summary for discussion purposes only. This MOU does not reference all of the detailed terms, conditions, representations, warranties, covenants and other provisions in relation to the Proposed Transaction that would be contained in the Definitive Agreements. For the avoidance of doubt, this MOU does not constitute an offer capable of acceptance and, except as expressly provided, will not give rise to any legally binding obligation on the part of any Party to consummate the Proposed Transaction. None of the Parties shall be legally bound with respect to the transactions contemplated herein unless and until such Parties have executed and delivered to each other the Definitive Agreements.

Notwithstanding anything contained in the above paragraph or any other provision contained herein, each Party expressly acknowledges and agrees that it shall be bound by the provisions of the Clauses titled "Confidentiality", "Intellectual Property", "Publication" and "Governing Law", to the extent applicable, with effect from the date of execution of this MOU.



In witness whereof, the Parties hereto caused this MOU to be executed on this 05 day of JULY, 2017.

<p>Signed for and on behalf of PELCOAT FORMULATIONS, Hyderabad.</p> <p><i>J. Chenna Reddy</i></p> <p>Name : <i>J. Chenna Reddy</i> Designation : <i>Manager-HR</i></p> <p>Witness</p> <p><i>S.K. Madhesh</i></p> <p>Name : <i>S.K. madhesh</i> Designation : <i>Manager-QE</i></p>	<p>Signed for and on behalf of Dr. K. V. Subba Reddy Institute of Pharmacy, Kurnool Dt.</p> <p><i>[Signature]</i></p> <p>Name : <i>Dr. G. Nagarajan</i> Designation: <i>Principal</i></p> <p>Witness</p> <p><i>B. V. Ramana</i></p> <p>Name : <i>Dr. B. V. Ramana</i> Designation : <i>Vice Principal</i></p> 
--	--





Umed Pharma Lab Pvt. Ltd.

An ISO 9001 : 2015 Certified Company & NABL Accredited Laboratory

Plot No. 50/A/1, Sy. No. 334 to 337, Bachupalli, Hyderabad M.M. Dist. Pin - 500090 Ph: 040-39301558, Email: sales@umedlabs.com

MEMORANDUM OF UNDERSTANDING (MOU)

Between

UMED Pharma Labs Pvt. Ltd, Plot No: 50/A/1, Sy. No. 334 to 337, Bachupalli, Hyderabad - 500090

And

**K. V. SUBBA REDDY INSTITUTE OF PHARMACY
Opp: Dupadu RS, N.H-44, Lakshmi Puram (Post), Kurnool Dt.**

For

**Facilitating collaborative research & development in
the areas of new drug discovery,
formulation development, clinical studies and
industry academia interaction for teaching and research**



This **MEMORANDUM OF UNDERSTANDING** (“**MOU**”) is executed on this 21 day of JULY, 2017 at KURNOOL by and between:

1. **Umed Pharma Labs Pvt Ltd**, a company incorporated and registered under the [*Indian*] Companies Act, 1956 and having its registered office at Plot No: 50/A/1, Sy. No. 334 to 337, Bachupalli, Hyderabad - 500090 (hereinafter referred to as “**UMED**”, which expression shall, unless repugnant to the meaning and context thereof, be deemed to include its successors and permitted assigns), of the **FIRST PART**; and
2. **Dr. K. V. Subba Reddy Institute of Pharmacy**, an affiliated college of Jawaharlal Nehru Technological University Anantapur, Anantapuramu and having its principal office at Opp. Dupadu RS, NH-44, Lakshmipuram (Post), Kurnool-518218 (hereinafter referred to as “**Dr. KVSP**”, which expression shall, unless repugnant to the meaning and context thereof, be deemed to include its successors and permitted assigns), of the **SECOND AND THE LAST PART**.

UMED and **Dr. KVSP** may hereinafter collectively be referred to as the “**Parties**” and individually each of them may be referred to as a “**Party**”.

WHEREAS:

- A. UMED is engaged in the business of developing, manufacturing and distributing pharmaceutical products for pharmaceutical companies and its business includes *inter alia*:
 - (a) manufacturing and/ or distribution of drugs at various dosage strengths including therapeutically equivalent ANDA based products and other products on a case-by-case basis;
 - (b) distribution of various drugs and marketing and/or licensing more than 60 (sixty) prescription drug product families in the United States of America;
 - (c) modified release of oral solid dosage forms as well as non-oral dosage forms of drugs such as nasal sprays, dry powder inhalers, patches and other alternative drug delivery platforms; and
 - (d) exchanging new scientific information and knowledge, transferring new technologies, exchanging students, scientists and technicians and commercializing products manufactured and/ or distributed by it through collaborative research;

(Hereinafter collectively referred to as the “**Business**”). The generic-drug portfolio of UMED consists of numerous products across a wide range of therapeutic areas that are the therapeutic equivalent of the brand-name pharmaceuticals.¹



¹ Umed to confirm that this accurately reflects its business activities.

- B. Dr. KVSP was established in the year 2007, with the object of imparting quality pharmacy education in India at graduate, postgraduate and doctoral levels. Dr. KVSP has the following mission and vision:

(a) Mission Statement

To impart knowledge, develop skills and competencies in students in pharmaceutical sciences and pharmacy practice

To develop and advance the knowledge, attitude and skills of pharmacists and faculty member who can provide comprehensive pharmaceutical care to patients, improve patient outcomes, and meet societal needs for safe and effective drug therapy.

To develop, promote and nurture research activities pursuing advances in pharmaceutical sciences and pharmacy practice. Translating research into healthcare practice is a cornerstone of our mission.

(b) Vision Statement

To be a leader in pharmaceutical sciences & pharmacy practice education, research and continuous professional development for pharmacists with the ultimate aim of providing competent patient care and drug development to national and international communities.

- C. The Parties are discussing the possibilities of arriving at an understanding for:

- (a) cooperation and joint research in (i) the areas of drug discovery, development and research leading to the award of Ph.D. degree as per the rules of the Jawaharlal Nehru Technological University Anantapur and as may be provided in the Ph.D. regulations of the Jawaharlal Nehru Technological University Anantapur; and (ii) such other areas as may be mutually agreed upon in writing between the Parties from time to time;
- (b) mutually engaging in bidding to private and public organizations for various scientific proposals and participating in various seminars or conferences as a single service provider. This understanding would include:
- (i) faculty exchange programs between members of the Parties and scientists for closer interactions; and
- (ii) sponsorship by UMED, of identified research projects to be undertaken by Ph. D. / M. Pharm candidates of the Dr. KVSP, which would also involve periodical meetings of the relevant students and supervisors, subject to mutual consultation of both the Parties.

The detailed modalities of the working of individual projects shall be arrived at after mutual discussions between the Parties and documented separately as project specific agreement / contracts before taking up the project;

(collectively referred to as the “**Proposed Transaction**”).



D. The Parties are entering into and executing this MOU, to set out their mutual understanding in relation to the Proposed Transaction. Each of the Parties understand that, unless specifically provided herein, this MOU is indicative of the principal terms of the Proposed Transaction and that this MOU does not constitute any commitment on part of either Party to consummate the Proposed Transaction.

NOW THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth in this MOU and other consideration, the sufficiency and adequacy of which is hereby acknowledged, the Parties agree as follows:

1. DEFINITIVE AGREEMENTS

The Parties acknowledge that their understanding in relation to the Proposed Transaction, as contemplated in this MOU, shall be subject to execution of definitive agreements for consummation of the Proposed Transaction between the Parties (“**Definitive Agreements**”). It is hereby clarified that the Definitive Agreements shall encapsulate the broad terms contained herein and may be supplemented by work plans to be developed jointly by the Parties, which would more specifically detail the activities to be carried out by the Parties under their cooperative programme and the envisaged contribution of each Party in respect thereof.²

2. OBLIGATIONS OF THE PARTIES

The Parties agree that the:

- (a) results of their research data which are collected, compiled and evaluated shall be shared and mutually exchanged by the Parties and their research findings in relation to areas identified by them will be published in public interest. However, Dr. KVSP shall hold complete unfettered editorial rights with respect to the findings that are to be published by the Parties, which rights shall be exercised by Dr. KVSP to safeguard the mutual interests of the Parties and to protect any intellectual property rights generated through such work;
- (b) instruments and equipments available at their respective facilities shall be shared mutually by the Parties to facilitate the objective intended to be achieved by the Proposed Transaction;
- (c) results of the collaborative research of the Parties may, subject to the consent of Dr. KVSP, be used for experimental and clinical trials and demonstrations, with active participation of the Parties;
- (d) scientific representatives of the Parties shall conduct periodical meetings (minimum half yearly) at such premises as may be mutually identified by the Parties, to discuss their progress on the objectives sought to be achieved by the Proposed Transaction;

² We would recommend that independent agreement be executed between the Parties for setting out their understanding in respect of the Proposed Transaction e.g. a separate research and development agreement should be entered into. This MOU has accordingly been suitably modified.



- (e) Parties may nominate members of their respective staff to work out the practical details of cooperation between the Parties and in general, to ensure proper and effective implementation of the Proposed Transaction. Such details, as agreed upon, will be confirmed by way of execution of the Definitive Agreements by the Parties.

3. TERM AND TERMINATION

This MOU will be in effect until execution of the Definitive Agreements by the Parties and may be terminated by the mutual written agreement of the Parties. Termination of this MOU shall however, not affect the binding obligations stated in Clause 4, Clause 6 (to the extent applicable), Clause 8.2 and Clause 10 of this MOU and the same shall be binding on the Parties.

Each of the Definitive Agreements shall be in effect initially for a period of 5 (five) years from the date of its execution and may be renewed subject to mutual written agreement of the Parties. Either Party may terminate a Definitive Agreement by written notification thereof to the other Party. Such notice must be received by the other Party at least 3 (three) months prior to the effective termination date of the relevant Definitive Agreement.

4. CONFIDENTIALITY

The Parties recognize that, by virtue of this MOU, they may be given and may have access to information relating to each Party, its affiliates, the Business and other proprietary information (“**Confidential Information**”) and accordingly undertake not to, without the prior written consent of the other Party, divulge and/ or communicate to any person, or use or exploit for any purpose whatsoever, any of the Confidential Information that any Party may receive or obtain as a result of entering into this MOU, and shall use reasonable endeavours to prevent their respective officers, employees or agents, if any, from doing so. These obligations and restrictions contained herein shall not apply to:

- (a) the extent that the Confidential Information is in the public domain other than by breach of this MOU;
- (b) the extent that the Confidential Information is required to be disclosed by any applicable law or any applicable regulatory requirements or by any regulatory body to whose jurisdiction the relevant Party is subject or with whose instructions it is customary to comply under notice to the other Party;
- (c) in so far as it is disclosed to the employees, directors or professional advisers, lenders, investors of any Party, provided that such Party shall procure that such persons treat the Confidential Information as confidential;
- (d) the extent that any of the Confidential Information is later acquired by a Party from a source not obligated to any other Party hereto, or its affiliates, to keep the Confidential Information confidential;



- (e) the extent that any of the Confidential Information is required by a Party for the purposes of enforcing or protecting or promoting its rights pursuant to this MOU, or for the purposes of performing the provisions of this MOU or performing the duties and other obligations of this MOU;
- (f) the extent that any of the Confidential Information was previously known or already in the lawful possession of a Party, prior to disclosure by the other Party; and
- (g) the extent that any information, similar to the Confidential Information, was independently developed by a Party without reference to any Confidential Information furnished by the other Party.

5. INDEMNITY

The Definitive Agreements shall contain mutual indemnity provisions for each Party (“**Indemnifying Party**”) to indemnify and hold harmless the other Party (“**Indemnified Party**”), from and against any and all liabilities, losses, damages, costs, claims, actions, proceedings, judgments, settlements, expenses or the like which may be suffered or incurred directly, but not consequentially, by the Indemnified Party as a result of:

- (a) any misrepresentation or breach of any representation or warranty made by the Indemnifying Party in the Definitive Agreement; or
- (b) breach of any covenant or obligation or agreement or undertaking contained in the Definitive Agreement by the Indemnifying Party; or
- (c) the negligent acts or omissions of Indemnifying Party or its agents or employees, pertaining to the activities to be carried by the Indemnifying Party pursuant to its obligations under the Definitive Agreement; provided however, that the Indemnifying Party shall not hold the Indemnified Party harmless from claims arising out of the negligence or wilful malfeasance of the Indemnified Party or its officers, agents, or employees or due to the negligent failure of the Indemnified Party to comply with any applicable governmental requirements or to adhere to the terms of the research as specified in the Definitive Agreement.

6. INTELLECTUAL PROPERTY

6.1. For the purposes of this Clause:

- (a) “**Invention**” shall mean any discovery, concept, or idea (whether or not patentable, and whether or not patent protection has been applied for or granted), made during the conduct of the study/ research relating to the Proposed Transaction during the tenure of the Definitive Agreements, and arising directly from the performance of the study/ research relating to the Proposed Transaction under the Definitive Agreements, including but not limited to processes, methods, software, tangible research products, formulas and techniques, improvements thereto, and know-how related thereto; and



- (b) **“Intellectual Property”** shall mean all intellectual and industrial property and all rights therein including, without limiting the generality of the foregoing, all Inventions, improvements, developments, discoveries, proprietary information, trade marks, trade mark applications, trade names, websites, internet domain names, logos, slogans, know-how, trade secrets, processes, designs (whether or not registerable and whether or not design rights subsist in them), and works in which copy-right may subsist (including computer software and preparatory and design materials therefore).
- 6.2. The Parties agree that the existing inventions and technologies of each of the Parties, as on date of execution of this MOU, are their separate property respectively and are not affected by this MOU and neither Party shall have any claims to or rights in such existing inventions and technologies of the other Party.
- 6.3. Further, in the event that any new Intellectual Property is generated as a result of performance of the obligations of the Parties under the Definitive Agreements (including any Intellectual Property generated as a result of any project and/ or joint research projects undertaken by the Parties under the Definitive Agreements), UMED shall take all responsibility for filing and processing of such collaborative Intellectual Property (including bearing of all expenses for any pre-grant or post-grant oppositions relating thereto). The Parties agree that all Intellectual Property jointly developed or acquired by them under the Definitive Agreements, shall be the sole property of UMED .
- 6.4. Dr. KVSP acknowledges and agrees that all Inventions made, written, discussed, developed, secured, obtained or learned during the tenure of the Definitive Agreements shall be the sole property of UMED including without limitation, all domestic and foreign patent rights, rights of registration or other protection under the copyright laws, or other rights, pertaining to the Inventions. Dr. KVSP further agrees that all services, products and Inventions that directly or indirectly result from its engagement with UMED shall be deemed to have arisen out of the course of the project/ research for which this MOU/ the Definitive Agreements are executed and accordingly, all rights associated therewith shall vest in UMED.
- 6.5. Dr. KVSP agrees that all applications for registration of any Intellectual Properties developed under the Definitive Agreements, shall be made in the name of UMED and shall be made by UMED only and Dr. KVSP shall provide all such information and assistance as may be deemed necessary in this regard to UMED .
- 6.6. The Parties will maintain confidentiality of all Intellectual Properties developed by any of them under the Definitive Agreement and shall not use the information in relation to such Intellectual Properties for any purpose other than those authorized in writing by the owner of Intellectual Property. However, wherever UMED 's services are employed for patent filling, sealing, protection know-how developed, Dr. KVSP shall automatically assign the know-how to UMED on a non-exclusive basis, the financial reimbursement for this assignment being the cost of the company assistance as above and the financial charges as mentioned in clause 6. Additionally, a lumpsum technology transfer charge to Dr. KVSP may be considered on a case-to-case basis.³

³ The exact intent of the highlighted protion is not clear.



7. DISPUTE RESOLUTION UNDER THE DEFINITIVE AGREEMENTS

- 7.1. The Definitive Agreements shall be governed and construed in accordance with the laws of India and each Party under the Definitive Agreements shall irrevocably submit to the exclusive jurisdiction of the courts at Kurnool, India in respect of any disputes, legal action or proceedings arising out of the provisions of the Definitive Agreements.
- 7.2. The Definitive Agreements shall also specify that:
- (a) any disputes or disagreements, arising out of, relating to or in connection with the terms and conditions of the Definitive Agreement or with respect to the validity, interpretation, implementation or alleged material breach of any provision thereof, whether during the subsistence of the Definitive Agreement or after its termination, shall be amicably settled between the Parties by mutual discussions between the senior management of the Parties;
 - (b) in the event that such dispute has not been amicably settled within sixty (60) days, then such a question or dispute shall be referred to the arbitration in accordance with the provisions of the [Indian] Arbitration and Conciliation Act, 1996. The arbitration shall be conducted by a sole arbitrator to be appointed jointly by the Parties. In the event of the Parties not being able to concur on the appointment of a sole arbitrator, such sole arbitrator shall be appointed as per the provisions of the [Indian] Arbitration and Conciliation Act, 1996. The award of the arbitrator shall be final and binding on the Parties. The place of arbitration shall be Bangalore and the language to be used in the arbitral proceedings shall be English. The arbitrator's fee shall be borne equally by the Parties. All other costs and expenses of the arbitration shall be borne by the Parties as the arbitrator may award.

8. PUBLICATIONS

- 8.1. Subject to Clause 2(a) above, the Parties reserve the right to publish or otherwise make public the data resulting from the studies conducted pursuant to the terms of the Definitive Agreements. The Party wishing to publish or make public its findings, shall submit any such manuscript or release to the other Party for comment prior to its publication or release.
- 8.2. Neither Party shall use the name of the other Party or any of its employees in connection with any press release, advertisement, promotional literature or any other publicity matters relating to this MOU or the Proposed Transaction without the express prior written consent of the other Party.
- 8.3. Except as otherwise required by law or regulation, neither Party shall release or distribute any materials or information containing the name of the other Party or any of its employees without prior written approval by an authorized representative of the non-releasing Party.



9. RELATIONSHIP OF PARTIES

The Parties shall act in their independent capacities in the performance of their respective functions under this MOU and no Party shall be considered as an officer, agent or employee of the other Party.

10. GOVERNING LAW

This MOU shall be governed and construed in accordance with the laws of India and each Party hereby irrevocably submits to the exclusive jurisdiction of the courts at Kurnool, India in respect of any disputes, legal action or proceedings arising out of the binding provisions of this MOU.

11. EFFECTIVE DATE AND DURATION OF MOU

- This MOU shall be effective from the date of its approval by competent authorities at both ends.
- The duration of the MOU shall be for a period of 5 year from the effective date from **21 July, 2017 to 30 June 2022.**
- During its tenancy, the MOU may be extended or terminated by a prior notice of not less than three months by either party. However, termination of the MOU will not in any manner affect the interests of the students/faculty/scientists who have been admitted to pursue a programme under the MOU.
- Any clause or article of the MOU may be modified or amended by mutual agreement of UMED PHARMA LAB Pvt.Ltd and Dr. KVSrip.

12. NOTICES

Any notice and other communication provided for in this MOU shall be in writing and shall be first transmitted by facsimile/electronic transmission and then confirmed by courier service or registered mail, in the manner as elected by the Party giving such notice to the following addresses:

In the case of notices to UMED:

Name : **U VENKATA REDDY**
Address: : Plot No 50/A/1,SY no 334 to 337,Bachupalli,Hyderabad-500090.
Phone: : 040-29304558.
Email: : sales@umedlabs.com

In the case of notices to Dr. KVSP:

Name : Dr. G. Nagarajan
Signature :
Address: : Dupadu RS, N.H-44, Lakshmipuram (Post), Kurnool
Phone: : +919440282181, +919704333789
Fax No: : 08518-287618
Email: : principalkvsrip@gmail.com



All notices shall be deemed to have been validly given on (i) the day immediately after the date of transmission with confirmed answer back, if transmitted by facsimile/electronic transmission, or (ii) the day of receipt, if transmitted by courier or registered airmail. Any Party may, from time to time, change its address or representative for receipt of notices provided for in this MOU by giving to the other Parties not less than 30 (thirty) days prior written notice.

13. AMENDMENT

It is mutually agreed that this MOU may be amended or modified renewed by the mutual written consent of the Parties.

14. SEVERABILITY

The invalidity or unenforceability of any term or provision of this MOU shall not affect the validity or enforceability of any other term or provision hereof.

15. ASSIGNMENT

Neither this MOU nor the rights or obligations hereunder shall be assignable or otherwise transferred or subcontracted by either of the Parties without the prior written consent of the other Parties and any attempted assignment in violation of the terms hereof shall be void.

16. COUNTERPARTS

This MOU may be executed in counterparts and each counterpart shall, taken together, constitute one and the same instrument.





17. NON-BINDING

This MOU is intended as a summary for discussion purposes only. This MOU does not reference all of the detailed terms, conditions, representations, warranties, covenants and other provisions in relation to the Proposed Transaction that would be contained in the Definitive Agreements. For the avoidance of doubt, this MOU does not constitute an offer capable of acceptance and, except as expressly provided, will not give rise to any legally binding obligation on the part of any Party to consummate the Proposed Transaction. None of the Parties shall be legally bound with respect to the transactions contemplated herein unless and until such Parties have executed and delivered to each other the Definitive Agreements.

Notwithstanding anything contained in the above paragraph or any other provision contained herein, each Party expressly acknowledges and agrees that it shall be bound by the provisions of the Clauses titled "Confidentiality", "Intellectual Property", "Publication" and "Governing Law", to the extent applicable, with effect from the date of execution of this MOU.



In witness whereof, the Parties hereto caused this MOU to be executed on this 21 day of JULY, 2017.

<p>Signed for and on behalf of UMED Pharma Labs Pvt. Ltd Hyderabad.</p> <p></p> <p>Name : A. Ravi Designation : Manager-HR</p> <p>Witness</p> <p></p> <p>Name : SK. Madanish Designation : PRO</p>	<p>Signed for and on behalf of Dr. K. V. Subba Reddy Institute of Pharmacy, Kurnool Dt.</p> <p></p> <p>Name : Dr. G. Nagarajan Designation: Principal</p> <p>Witness</p> <p></p> <p>Name : Dr. B. V. Ramana Designation :Vice Principal</p>
---	--



MEMORANDUM OF UNDERSTANDING (MOU)

Between

**Analog Labs, Prashanti Nagar, IDA, Balanagar, Hyderabad,
Telangana 500072**

And

**K. V. SUBBA REDDY INSTITUTE OF PHARMACY
Opp: Dupadu RS, N.H-44, Lakshmi Puram (Post), Kurnool Dt.**

For

**Facilitating collaborative research & development in
the areas of new drug discovery,
formulation development, clinical studies and
industry academia interaction for teaching and research**

This **MEMORANDUM OF UNDERSTANDING** (“MOU”) is executed on this **FIRST** day of **JUNE**, 2019 at **KURNOOL** by and between:

1. **Analog Labs**, a company incorporated and registered under the [*Indian*] Companies Act, 1956 and having its registered office at Prashanti Nagar, IDA, Balanagar, Hyderabad, Telangana 500072.(hereinafter referred to as “**Analog labs**”, which expression shall, unless repugnant to the meaning and context thereof, be deemed to include its successors and permitted assigns), of the **FIRST PART**; and
2. **Dr. K. V. Subba Reddy Institute of Pharmacy**, anaffiliated college of Jawaharlal Nehru Technological University Anantapur, Anantapuramuand having its principal office at Opp. Dupadu RS, N.H-44, Lakshmi Puram (Post), Kurnool Dt.(hereinafter referred to as “**Dr. KVSP**”, which expression shall, unless repugnant to the meaning and context thereof, be deemed to include its successors and permitted assigns), of the **SECOND AND THE LAST PART**.

Analog and **Dr. KVSP** may hereinafter collectively be referred to as the “**Parties**” and individually each of them may be referred to as a “**Party**”.

WHEREAS:

- A. **Analog labs** is providing Analytical Testing services for the industries of Bulk Drugs, Drug Intermediates, Pharmaceutical Formulations, Cosmetics, Chemicals, Water and Minerals:
 - (a) assist manufacturer, research facility, academic institution or organization in finding independent, contract pharmaceutical testing laboratories to perform all your pharmaceuticals studies, research projects, experimentation, laboratory testing and analysis;
 - (b) shoulders the responsibility of bridging the gap between academic training and Industry requirements by providing the proper training, tailor-made by a group of industry experts
 - (c) prepares productive and inspired chemists/analysts/pharmacists from the day one of their joining the industry and bring value addition for both employee and employer
 - (d) exchanging new scientific information and knowledge, transferring new technologies, exchanging students, scientists and technicians and commercializing products manufactured and/ or distributed by it through collaborative research;

(hereinafter collectively referred to as the “**Business**”). The generic-drug portfolio of **Analog labs** consists of numerous products across a wide range of therapeutic areas that are the therapeutic equivalent of the brand-name pharmaceuticals.¹

¹ Bell to confirm that this accurately reflects its business activities.

B. **Dr. KVSP** was established in the year 2007 with the object of imparting quality pharmacy education in India at graduate, postgraduate and doctoral levels. **Dr. KVSP** has the following mission and vision:

(a) Mission Statement

To impart knowledge, develop skills and competencies in students in pharmaceutical sciences and pharmacy practice

To develop and advance the knowledge, attitude and skills of pharmacists and faculty member who can provide comprehensive pharmaceutical care to patients, improve patient outcomes, and meet societal needs for safe and effective drug therapy.

To develop, promote and nurture research activities pursuing advances in pharmaceutical sciences and pharmacy practice. Translating research into healthcare practice is a cornerstone of our mission.

(b) Vision Statement

To be a leader in pharmaceutical sciences & pharmacy practice education, research and continuous professional development for pharmacists with the ultimate aim of providing competent patient care and drug development to national and international communities.

C. The Parties are discussing the possibilities of arriving at an understanding for:

(a) cooperation and joint research in (i) the areas of drug discovery, development and research leading to the award of Ph.D. degree as per the rules of the Jawaharlal Nehru Technological University Anantapur and as may be provided in the Ph.D. regulations of the Jawaharlal Nehru Technological University Anantapur; and (ii) such other areas as may be mutually agreed upon in writing between the Parties from time to time;

(b) mutually engaging in bidding to private and public organizations for various scientific proposals and participating in various seminars or conferences as a single service provider. This understanding would include:

(i) faculty exchange programs between members of the Parties and scientists for closer interactions; and

(ii) sponsorship by **Analog labs**, of identified research projects to be undertaken by Ph. D. / M.Pharm candidates of the **Dr. KVSP**, which would also involve periodical meetings of the relevant students and supervisors, subject to mutual consultation of both the Parties.

The detailed modalities of the working of individual projects shall be arrived at after mutual discussions between the Parties and documented separately as project specific agreement / contracts before taking up the project;

- D. The Parties are entering into and executing this MOU, to set out their mutual understanding in relation to the Proposed Transaction. Each of the Parties understand that, unless specifically provided herein, this MOU is indicative of the principal terms of the Proposed Transaction and that this MOU does not constitute any commitment on part of either Party to consummate the Proposed Transaction.

NOW THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth in this MOU and other consideration, the sufficiency and adequacy of which is hereby acknowledged, the Parties agree as follows:

1. DEFINITIVE AGREEMENTS

The Parties acknowledge that their understanding in relation to the Proposed Transaction, as contemplated in this MOU, shall be subject to execution of definitive agreements for consummation of the Proposed Transaction between the Parties ("**Definitive Agreements**"). It is hereby clarified that the Definitive Agreements shall encapsulate the broad terms contained herein and may be supplemented by work plans to be developed jointly by the Parties, which would more specifically detail the activities to be carried out by the Parties under their cooperative programme and the envisaged contribution of each Party in respect thereof.²

2. OBLIGATIONS OF THE PARTIES

The Parties agree that the:

- (a) results of their research data which are collected, compiled and evaluated shall be shared and mutually exchanged by the Parties and their research findings in relation to areas identified by them will be published in public interest. However, Dr. KVSP shall hold complete unfettered editorial rights with respect to the findings that are to be published by the Parties, which rights shall be exercised by Dr. KVSP to safeguard the mutual interests of the Parties and to protect any intellectual property rights generated through such work;
- (b) instruments and equipments available at their respective facilities shall be shared mutually by the Parties to facilitate the objective intended to be achieved by the Proposed Transaction;
- (c) results of the collaborative research of the Parties may, subject to the consent of Dr. KVSP, be used for experimental and clinical trials and demonstrations, with active participation of the Parties;
- (d) scientific representatives of the Parties shall conduct periodical meetings (minimum half yearly) at such premises as may be mutually identified by the Parties, to discuss their progress on the objectives sought to be achieved by the Proposed Transaction;

²We would recommend that independent agreement be executed between the Parties for setting out their understanding in respect of the Proposed Transaction e.g. a separate research and development agreement should be entered into. This MOU has accordingly been suitably modified.

- (e) Parties may nominate members of their respective staff to work out the practical details of cooperation between the Parties and in general, to ensure proper and effective implementation
- (f) of the Proposed Transaction. Such details, as agreed upon, will be confirmed by way of execution of the Definitive Agreements by the Parties.

3. TERM AND TERMINATION

This MOU will be in effect until execution of the Definitive Agreements by the Parties and may be terminated by the mutual written agreement of the Parties. Termination of this MOU shall however, not affect the binding obligations stated in Clause 4, Clause 6 (to the extent applicable), Clause 8.2 and Clause 10 of this MOU and the same shall be binding on the Parties.

Each of the Definitive Agreements shall be in effect initially for a period of 5 (five) years from the date of its execution and may be renewed subject to mutual written agreement of the Parties. Either Party may terminate a Definitive Agreement by written notification thereof to the other Party. Such notice must be received by the other Party at least 3 (three) months prior to the effective termination date of the relevant Definitive Agreement.

4. CONFIDENTIALITY

The Parties recognize that, by virtue of this MOU, they may be given and may have access to information relating to each Party, its affiliates, the Business and other proprietary information ("**Confidential Information**") and accordingly undertake not to, without the prior written consent of the other Party, divulge and/ or communicate to any person, or use or exploit for any purpose whatsoever, any of the Confidential Information that any Party may receive or obtain as a result of entering into this MOU, and shall use reasonable endeavors to prevent their respective officers, employees or agents, if any, from doing so. This obligations and restrictions contained herein shall not apply to:

- (a) the extent that the Confidential Information is in the public domain other than by breach of this MOU;
- (b) the extent that the Confidential Information is required to be disclosed by any applicable law or any applicable regulatory requirements or by any regulatory body to whose jurisdiction the relevant Party is subject or with whose instructions it is customary to comply under notice to the other Party;
- (c) in so far as it is disclosed to the employees, directors or professional advisers, lenders, investors of any Party, provided that such Party shall procure that such persons treat the Confidential Information as confidential;
- (d) the extent that any of the Confidential Information is later acquired by a Party from a source not obligated to any other Party hereto, or its affiliates, to keep the Confidential Information confidential;

- (e) the extent that any of the Confidential Information is required by a Party for the purposes of enforcing or protecting or promoting its rights pursuant to this MOU, or for the purposes of performing the provisions of this MOU or performing the duties and other obligations of this MOU;
- (f) the extent that any of the Confidential Information was previously known or already in the lawful possession of a Party, prior to disclosure by the other Party; and
- (g) the extent that any information, similar to the Confidential Information, was independently developed by a Party without reference to any Confidential Information furnished by the other Party.

5. INDEMNITY

The Definitive Agreements shall contain mutual indemnity provisions for each Party (“**Indemnifying Party**”) to indemnify and hold harmless the other Party (“**Indemnified Party**”), from and against any and all liabilities, losses, damages, costs, claims, actions, proceedings, judgments, settlements, expenses or the like which may be suffered or incurred directly, but not consequentially, by the Indemnified Party as a result of:

- (a) any misrepresentation or breach of any representation or warranty made by the Indemnifying Party in the Definitive Agreement; or
- (b) breach of any covenant or obligation or agreement or undertaking contained in the Definitive Agreement by the Indemnifying Party; or
- (c) the negligent acts or omissions of Indemnifying Party or its agents or employees, pertaining to the activities to be carried by the Indemnifying Party pursuant to its obligations under the Definitive Agreement; provided however, that the Indemnifying Party shall not hold the Indemnified Party harmless from claims arising out of the negligence or wilful malfeasance of the Indemnified Party or its officers, agents, or employees or due to the negligent failure of the Indemnified Party to comply with any applicable governmental requirements or to adhere to the terms of the research as specified in the Definitive Agreement.

6. INTELLECTUAL PROPERTY

6.1. For the purposes of this Clause:

- (a) “**Invention**” shall mean any discovery, concept, or idea (whether or not patentable, and whether or not patent protection has been applied for or granted), made during the conduct of the study/research relating to the Proposed Transaction during the tenure of the Definitive Agreements, and arising directly from the performance of the study/research relating to the Proposed Transaction under the Definitive Agreements, including but not limited to processes, methods, software, tangible research products, formulas and techniques, improvements thereto, and know-how related thereto; and

- (b) “**Intellectual Property**” shall mean all intellectual and industrial property and all rights therein including, without limiting the generality of the foregoing, all Inventions, improvements, developments, discoveries, proprietary information, trademarks, trade mark applications, trade names, websites, internet domain names, logos, slogans, know-how, trade secrets, processes, designs (whether or not registerable and whether or not design rights subsist in them), and works in which copy-right may subsist (including computer software and preparatory and design materials therefore).
- 6.2. The Parties agree that the existing inventions and technologies of each of the Parties, as on date of execution of this MOU, are their separate property respectively and are not affected by this MOU and neither Party shall have any claims to or rights in such existing inventions and technologies of the other Party.
- 6.3. Further, in the event that any new Intellectual Property is generated as a result of performance of the obligations of the Parties under the Definitive Agreements (including any Intellectual Property generated as a result of any project and/ or joint research projects undertaken by the Parties under the Definitive Agreements), Analog labs shall take all responsibility for filing and processing of such collaborative Intellectual Property (including bearing of all expenses for any pre-grant or post-grant oppositions relating thereto). The Parties agree that all Intellectual Property jointly developed or acquired by them under the Definitive Agreements, shall be the sole property of Analog labs.
- 6.4. Dr. KVSP acknowledges and agrees that all Inventions made, written, discussed, developed, secured, obtained or learned during the tenure of the Definitive Agreements shall be the sole property of Analog labs including without limitation, all domestic and foreign patent rights, rights of registration or other protection under the copyright laws, or other rights, pertaining to the Inventions. Dr. KVSP further agrees that all services, products and Inventions that directly or indirectly result from its engagement with Analog labs shall be deemed to have arisen out of the course of the project/ research for which this MOU/ the Definitive Agreements are executed and accordingly, all rights associated therewith shall vest in Analog labs.
- 6.5. Dr. KVSP agrees that all applications for registration of any Intellectual Properties developed under the Definitive Agreements, shall be made in the name of Analog labs and shall be made by Analog labs only and Dr. KVSP shall provide all such information and assistance as may be deemed necessary in this regard to Analog labs.
- 6.6. The Parties will maintain confidentiality of all Intellectual Properties developed by any of them under the Definitive Agreement and shall not use the information in relation to such Intellectual Properties for any purpose other than those authorized in writing by the owner of Intellectual Property. However, wherever Analog labs’s services are employed for patent filling, sealing, protection know-how developed, Dr. KVSP shall automatically assign the know-how to Analog labson a non-exclusive basis, the financial reimbursement for this assignment being the cost of the company assistance as above and the financial charges as mentioned in clause 6. Additionally, a lumpsum technology transfer charge to Dr. KVSP may be considered on a case-to-case basis.³

7. DISPUTE RESOLUTION UNDER THE DEFINITIVE AGREEMENTS

- 7.1. The Definitive Agreements shall be governed and construed in accordance with the laws of India and each Party under the Definitive Agreements shall irrevocably submit to the exclusive jurisdiction of the courts at Kurnool, India in respect of any disputes, legal action or proceedings arising out of the provisions of the Definitive Agreements.
- 7.2. The Definitive Agreements shall also specify that:
- (a) any disputes or disagreements, arising out of, relating to or in connection with the terms and conditions of the Definitive Agreement or with respect to the validity, interpretation, implementation or alleged material breach of any provision thereof, whether during the subsistence of the Definitive Agreement or after its termination, shall be amicably settled between the Parties by mutual discussions between the senior management of the Parties;
 - (b) in the event that such dispute has not been amicably settled within sixty (60) days, then such a question or dispute shall be referred to the arbitration in accordance with the provisions of the [Indian] Arbitration and Conciliation Act, 1996. The arbitration shall be conducted by a sole arbitrator to be appointed jointly by the Parties. In the event of the Parties not being able to concur on the appointment of a sole arbitrator, such sole arbitrator shall be appointed as per the provisions of the [Indian] Arbitration and Conciliation Act, 1996. The award of the arbitrator shall be final and binding on the Parties. The place of arbitration shall be Bangalore and the language to be used in the arbitral proceedings shall be English. The arbitrator's fee shall be borne equally by the Parties. All other costs and expenses of the arbitration shall be borne by the Parties as the arbitrator may award.

8. PUBLICATIONS

- 8.1. Subject to Clause 2(a) above, the Parties reserve the right to publish or otherwise make public the data resulting from the studies conducted pursuant to the terms of the Definitive Agreements. The Party wishing to publish or make public its findings, shall submit any such manuscript or release to the other Party for comment prior to its publication or release.
- 8.2. Neither Party shall use the name of the other Party or any of its employees in connection with any press release, advertisement, promotional literature or any other publicity matters relating to this MOU or the Proposed Transaction without the express prior written consent of the other Party.
- 8.3. Except as otherwise required by law or regulation, neither Party shall release or distribute any materials or information containing the name of the other Party or any of its employees without prior written approval by an authorized representative of the non-releasing Party.

9. RELATIONSHIP OF PARTIES

The Parties shall act in their independent capacities in the performance of their respective functions under this MOU and no Party shall be considered as an officer, agent or employee of the other Party.

10. GOVERNING LAW

This MOU shall be governed and construed in accordance with the laws of India and each Party hereby irrevocably submits to the exclusive jurisdiction of the courts at KURNOOL, India in respect of any disputes, legal action or proceedings arising out of the binding provisions of this MOU.

11. EFFECTIVE DATE AND DURATION OF MOU

- a) This MOU shall be effective from the date of its approval by competent authorities at both ends.
- b) The duration of the MOU shall be for a period of 5 year from the effective date from 15 July, 2017 to 30 June 2022.
- c) During its tenancy, the MOU may be extended or terminated by a prior notice of not less than three months by either party. However, termination of the MOU will not in any manner affect the interests of the students/faculty/scientists who have been admitted to pursue a programme under the MOU.
- d) Any clause or article of the MOU may be modified or amended by mutual agreement of AODH Pharmaceuticals and Dr. KVSRIIP.

12. NOTICES

Any notice and other communication provided for in this MOU shall be in writing and shall be first transmitted by facsimile/electronic transmission and then confirmed by courier service or registered mail, in the manner as elected by the Party giving such notice to the following addresses:

In the case of notices to AODH:

Attn: K.Anupama Reddy
Address: 3rd Floor, Plot No.86, Prashanthi Nagar, Kukatpally, Hyderabad -500072
Phone: 9618252442
Email: analoglbs@gmail.com

In the case of notices to Dr. KVSP:

Attn: Dr. G. Nagarajan
Signature:
Address: Opp. Dupadu RS, NH-44, Lakshmipuram (Post), Kurnool
Phone: +919440282181, +91970333789
Fax No: 08518-287618
Email: principalkvsrip@gmail.com

All notices shall be deemed to have been validly given on (i) the day immediately after the date of transmission with confirmed answer back, if transmitted by facsimile/electronic transmission, or (ii) the day of receipt, if transmitted by courier or registered airmail. Any Party may, from time to time, change its address or representative for receipt of notices provided for in this MOU by giving to the other Parties not less than 30 (thirty) days prior written notice.

13. AMENDMENT

It is mutually agreed that this MOU may be amended or modified renewed by the mutual written consent of the Parties.

14. SEVERABILITY

The invalidity or unenforceability of any term or provision of this MOU shall not affect the validity or enforceability of any other term or provision hereof.

15. ASSIGNMENT

Neither this MOU nor the rights or obligations hereunder shall be assignable or otherwise transferred or subcontracted by either of the Parties without the prior written consent of the other Parties and any attempted assignment in violation of the terms hereof shall be void.

16. COUNTERPARTS




This MOU may be executed in counterparts and each counterpart shall, taken together, constitute one and the same instrument.

17. NON-BINDING

This MOU is intended as a summary for discussion purposes only. This MOU does not reference all of the detailed terms, conditions, representations, warranties, covenants and other provisions in relation to the Proposed Transaction that would be contained in the Definitive Agreements. For the avoidance of doubt, this MOU does not constitute an offer capable of acceptance and, except as expressly provided, will not give rise to any legally binding obligation on the part of any Party to consummate the Proposed Transaction. None of the Parties shall be legally bound with respect to the transactions contemplated herein unless and until such Parties have executed and delivered to each other the Definitive Agreements.

Notwithstanding anything contained in the above paragraph or any other provision contained herein, each Party expressly acknowledges and agrees that it shall be bound by the provisions of the Clauses titled "Confidentiality", "Intellectual Property", "Publication" and "Governing Law", to the extent applicable, with effect from the date of execution of this MOU.

In witness whereof, the Parties hereto caused this MOU to be executed on this 21 day of JULY, 2019.

Signed for and on behalf of Analog labs, Hyderabad.  Name : K. Anupama Reddy Designation : Director Witness Name : Designation :	Signed for and on behalf of Dr. K. V. Subba Reddy College of Pharmacy, Kurnool.  Name : Dr. G. Nagarajan Designation : Principal Witness Dr. B. V. Ramana  Name : Designation : Vice Principal
---	--

A Analog Labs

Analytical Testing Laboratory & Training Centre

CERTIFICATE OF TRAINING

This is to certify that M. Mounica R.No. 19ERJR0033
has undergone training programme on
Instrumental & Chemical Analysis
from 10th Aug-2022 to 10th Sep-2022
organized by Analog Labs, Hyderabad. During training
programme, the candidate was imparted training
on HPLC, UV & Wet Analysis.
The performance of the candidate during the training
period was found to be satisfactory.



Director

Analog Labs
Analytical Testing Laboratory & Training Centre
3rd Floor, Plot No. 86,
Near Venkateshwara Temple,
Prashanthi Nagar, Hyderabad - 500 072, I.A.P.
Phone 9618252442


Instructor



SODUM
DRUGS & PHARMACEUTICALS (P) LTD

Date: 07.09.2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Miss. C FARHANA, D/o C MAHFOOZ, Reg.No. 19ER1R0057** is a bonafide student of **Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH**. She has undergone industrial training in our organization from **10.08.2022 to 03.09.2022**, as a part of partial fulfilment of her B. Pharmacy course.

During the training, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

For SODUM DRUGS & PHARMACEUTICALS PVT.LTD

S. Srinivas
AUTHORIZED SIGNATURE





Umed Pharma Lab Pvt. Ltd.

An ISO 9001 : 2015 Certified Company & NABL Accredited Laboratory

Plot No. 50/A/1, Sy.No. 334 to 337, Bachupalli, Hyderabad. M.M. Dist. Pin - 500090. Ph. 040-29304558. Email: umeda@umedpharma.com

Date: 6th SEP, 2022

INDUSTRIAL TRAINING CERTIFICATE

This is to certify that Miss. S LAKSHMI PADMAVATHI, D/o S NARAYANA is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNODL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022 as part of partial fulfilment of her B. Pharmacy course bearing Hall Ticket No 19ER1R00A0. She has been trained in the following aspects of our organization.

- 1) Aspects of Schedule "M"
- 2) Pharmacological Bio-assays.
- 3) Formulation aspects.

During this aforesaid period, we found her hardworking, sincere and learning attitude.

We wish her A Bright Future

For UMED PHARMA LABS



Date: 05-09-2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Miss. B POONAM SAI, D/o B NAGARAJU** is a bonafide student of **DR. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH**. She has undergone industrial training in our organization from **10-08-2022 TO 03-09-2022**, as part of partial fulfilment of her B.Pharmacy course bearing Hall Ticket no- **19ER1R0006**.

During the training period, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

FOR PELCOAT FORMULATIONS


Authorized Signature



SODUM DRUGS & PHARMACEUTICALS (P) LTD

Date: 07.09.2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Miss. S SANIHA, D/o S NAZEER, Reg.No. 19ER1R0083** is a bonafide student of **Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH**. She has undergone industrial training in our organization from **10.08.2022 to 03.09.2022**, as a part of partial fulfilment of her B. Pharmacy course.

During the training, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

For SODUM DRUGS & PHARMACEUTICALS PVT.LTD

S. Indra
AUTHORIZED SIGNATURE





SODUM
DRUGS & PHARMACEUTICALS (P) LTD

Date: 07.09.2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Miss. SANDRA SREELATHA, D/o SANDRA THIMMAIAH, Reg.No. 19ER1R0079 is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022, as a part of partial fulfilment of her B. Pharmacy course.

During the training, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

For SODUM DRUGS & PHARMACEUTICALS PVT.LTD

AUTHORIZED SIGNATURE



FLAT NO.7, D.NO. 1-2-30, SRI SAI PRIYA RESIDENCY, NEAR BRINDAVAN COLONY, NIZAMPET ROAD,
HYDERABAD - 500072, T.S. INDIA.
Mail : info@sodumdrugs.com, indra@sodumdrugs.com Cell : 9591044330

realme Shot by sowmya..❤️

realme 9i 5G 2023 02 05 19:57



Umed Pharma Lab Pvt. Ltd.

An ISO 9001 : 2015 Certified Company & NABL Accredited Laboratory

Plot No. 50/A/1, Sy.No. 334 to 337, Bachupalli, Hyderabad. M.M. Dist. Pin - 500090. Ph: 040-29304558. Email: sales@umedlabs.com

Date: 6th SEP, 2022

INDUSTRIAL TRAINING CERTIFICATE

This is to certify that Miss. C SOWMYA, D/o C RAGHU RAMI REDDY is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022 as part of partial fulfilment of her B. Pharmacy course bearing Hall Ticket No 19ER1R0091. She has been trained in the following aspects of our organization.

- 1) Aspects of Schedule "M"
- 2) Pharmacological Bio-assays.
- 3) Formulation aspects.

During this aforesaid period, we found her hardworking, sincere and learning attitude.

We wish her A Bright Future

For UMED PHARMA LABS


Authorized Signature



realme
Shot by sowmya..
realme 9i 5G 2023 02 20 17:11

Date: 05-09-2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Miss. K NAVANEETHA, D/o K CHANDRASEKAR REDDY** is a bonafide student of **DR. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH.** She has undergone industrial training in our organization from **10-08-2022 TO 03-09-2022,** as part of partial fulfilment of her B.Pharmacy course bearing Hall Ticket no- **19ER1R0025.**

During the training period, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

FOR PELCOAT FORMULATIONS



Authorized Signature

A Analog Labs

Analytical Testing Laboratory & Training Centre


CERTIFICATE OF TRAINING

This is to certify that Pasi Sneha Reddy
has undergone training programme on Instrumental & Chemical Analysis
from 10th - Aug - 2022 to 10th - Sep - 2022
organized by Analog Labs, Hyderabad. During training
programme, the candidate was imparted training
on HPLC, UV & Wet Analysis.
The performance of the candidate during the training
period was found to be satisfactory.



Director

Analog Labs
Analytical Testing Laboratory & Training Centre
3rd Floor, Plot No. 85,
Near Venkateshwara Temple,
Prashanthi Nagar, Hyderabad - 500 042 (H)
Phone : 9618252442


Instructor



Umed Pharma Lab Pvt. Ltd.

An ISO 9001 : 2015 Certified Company & NABL Accredited Laboratory

Plot No. 50/A/1, Sy.No. 334 to 337, Bachupalli, Hyderabad. M.M. Dist. Pin - 500090. Ph: 040-29304558. Email: sales@umedlabs.com

Date: 6th SEP, 2022

INDUSTRIAL TRAINING CERTIFICATE


This is to certify that Miss. D MADHURI, D/o D YELLA REDDY is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022 as part of partial fulfilment of her B. Pharmacy course bearing Hall Ticket No 19ER1R0092. She has been trained in the following aspects of our organization.

- 1) Aspects of Schedule "M"
- 2) Pharmacological Bio-assays.
- 3) Formulation aspects.

During this aforesaid period, we found her hardworking, sincere and learning attitude.

We wish her A Bright Future

For UMED PHARMA LABS


Authorized Signature





SODUM
DRUGS & PHARMACEUTICALS (P) LTD

Date: 07.09.2022


TO WHOM SO EVER IT MAY CONCERN

This is to certify that Miss. G PREMALATHA, D/o G PEDDA SWAMULU, Reg.No. 19ER1R0064 is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022, as a part of partial fulfilment of her B. Pharmacy course.

During the training, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

For SODUM DRUGS & PHARMACEUTICALS PVT.LTD


AUTHORIZED SIGNATURE

CERTIFICATE OF TRAINING

This is to certify that Pothuraju Malathi
has undergone training programme on 19ER1R0041
Instrumental & Chemical Analysis
from 10th - Aug - 2022 to 10th - Sep - 2022
organized by Analog Labs, Hyderabad. During training
programme, the candidate was imparted training
on HPLC, UV & Wet Analysis.
The performance of the candidate during the training
period was found to be satisfactory.



Director

Analog Labs
Analytical Testing Laboratory & Training Centre
3rd Floor, Plot No. 86,
Near Venkateshwara Temple,
Prashanthi Nagar, Hyderabad - 500 072, I.A.P.
Phone: 9618252442


Instructor

CERTIFICATE OF TRAINING

This is to certify that Shaik Nuzraath
has undergone training programme on Sl.No. 19 ERJR0047
Instrumental & Chemical Analysis
from 10th-Aug-2022 to 10th-sep-2022
organized by Analog Labs, Hyderabad. During training
programme, the candidate was imparted training
on HPLC, UV & Wet Analysis.
The performance of the candidate during the training
period was found to be satisfactory.



Director

Analog Labs
Analytical Testing Laboratory & Training Centre
3rd Floor, Plot No. 86
Near Venkateshwara Temple,
Prashanthi Nagar, Hyderabad - 500 092 (A.P.)
Phone 9618252442

Instructor



Umed Pharma Lab Pvt. Ltd.

An ISO 9001 : 2015 Certified Company & NABL Accredited Laboratory

Plot No. 50/A/1, Sy.No. 334 to 337, Bachupalli, Hyderabad. M.M. Dist. Pin - 500090. Ph: 040-29304558. Email: sales@umedlabs.com

Date: 6th SEP, 2022

INDUSTRIAL TRAINING CERTIFICATE

This is to certify that Miss. KUNCHA MANASA, D/o K MADAN GOPAL REDDY is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022 as part of partial fulfilment of her B. Pharmacy course bearing Hall Ticket No 19ER1R0093. She has been trained in the following aspects of our organization.

- 1) Aspects of Schedule "M"
- 2) Pharmacological Bio-assays.
- 3) Formulation aspects.

During this aforesaid period, we found her hardworking, sincere and learning attitude.

We wish her A Bright Future

For UMED PHARMA LABS

A. Rajesh
Authorized Signature



CERTIFICATE OF TRAINING

This is to certify that Gujjula Jahnavi
has undergone training programme on ^{R.No.19ER1R0018}
Instrumental & Chemical Analysis
from 10th Aug - 2022 to 10th Sep - 2022
organized by Analog Labs, Hyderabad. During training
programme, the candidate was imparted training
on HPLC, UV & Wet Analysis.
The performance of the candidate during the training
period was found to be satisfactory.



Director

Analog Labs
Analytical Testing Laboratory & Training Centre
3rd Floor, Plot No. 86,
Near Venkateshwara Temple,
Prashanthi Nagar, Hyderabad - 500 052, India
Phone : 9618252442

Instructor



**SODUM
DRUGS & PHARMACEUTICALS (P) LTD**

Date: 07.09.2022


TO WHOM SO EVER IT MAY CONCERN

This is to certify that Miss. M MOUNIKA, D/o M SHANTHA KUMAR, Reg.No. 19ER1R0072 is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022, as a part of partial fulfilment of her B. Pharmacy course.

During the training, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

For SODUM DRUGS & PHARMACEUTICALS PVT.LTD


AUTHORIZED SIGNATURE



FLAT NO.7, D.NO. 1-2-30, SRI SAI PRIYA RESIDENCY, NEAR BRINDAVAN COLONY, NIZAMPET ROAD,
HYDERABAD - 500072, T.S. INDIA.

Mail : info@sodumdrugs.com, indra@sodumdrugs.com Cell : 9591044330

Date: 05-09-2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Miss. C SANDHYA, D/o C MOHAN** is a bonafide student of **DR. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH**. She has undergone industrial training in our organization from **10-08-2022 TO 03-09-2022**, as part of partial fulfilment of her B.Pharmacy course bearing Hall Ticket no- **19ER1R0010**.

During the training period, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

FOR PELCOAT FORMULATIONS



Authorized Signature

Sy.No. 13, Kucharam Village, Toopran Mandal, Medak Dist. - 502 336 (T.S) INDIA.

Ph: 08454 - 250183, Fax: 08454 - 250 182.

E-mail: md@pelcoat.com www.pelcoatformulations.in

CERTIFICATE OF TRAINING

This is to certify that Shaik, Amreen
has undergone training programme on R.No. 19ER1R0045
Instrumental & Chemical Analysis
from 10th - Aug - 2022 to 10th - Sep - 2022
organized by Analog Labs, Hyderabad. During training
programme, the candidate was imparted training
on HPLC, UV & Wet Analysis.
The performance of the candidate during the training
period was found to be satisfactory.



Director

Analog Labs
Analytical Testing Laboratory & Training Centre
3rd Floor, Plot No. 86
Near Venkateshwara Temple
Prashanthi Nagar, Hyderabad - 500 097, (A.P.)
Phone: 9618252442

Instructor

Date: 05-09-2022

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Miss. K GEETHA MOUNIKA, D/o K LAKSHMINARAYANA GOUD** is a bonafide student of **DR. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH**. She has undergone industrial training in our organization from **10-08-2022 TO 03-09-2022**, as part of partial fulfilment of her B.Pharmacy course bearing Hall Ticket no- **19ER1R0020**.

During the training period, she interacted with Quality control, Quality Assurance & Production departments and acquired basic knowledge in these areas.

During this aforesaid period, we found her hard-working, sincere and learning attitude.

FOR PELCOAT FORMULATIONS



Authorized Signature



Umed Pharma Lab Pvt. Ltd.

An ISO 9001 : 2015 Certified Company & NABL Accredited Laboratory

Plot No. 50/A/1, Sy.No. 334 to 337, Bachupalli, Hyderabad. M.M. Dist. Pin - 500090. Ph: 040-29304558. Email: sales@umedlabs.com

Date: 6th SEP, 2022

INDUSTRIAL TRAINING CERTIFICATE

This is to certify that Miss. M MANASA, D/o M VENKATESWARA REDDY is a bonafide student of Dr. K.V. SUBBA REDDY INSTITUTE OF PHARMACY, DUPADU, KURNOOL, ANDHRA PRADESH. She has undergone industrial training in our organization from 10.08.2022 to 03.09.2022 as part of partial fulfilment of her B. Pharmacy course bearing Hall Ticket No 19ER1R0097. She has been trained in the following aspects of our organization.

- 1) Aspects of Schedule "M"
- 2) Pharmacological Bio-assays.
- 3) Formulation aspects.

During this aforesaid period, we found her hardworking, sincere and learning attitude.

We wish her A Bright Future

For UMED PHARMA LABS

Authorized Signature

